Bausch Health Reveals Promising Results in Clinical Trials of Amiselimod and Rifaximin

Bausch Health Companies Inc., a global pharmaceutical company, has announced encouraging outcomes from recent trials presented at two international healthcare conferences. Salix Pharmaceuticals, a division of Bausch Health, shared data from its Amiselimod trials at Digestive Disease Week (DDW) 2024 in Washington, D.C., and post hoc analyses of Rifaximin at the International Liver Congress 2024 (ILC 2024) in Milan, Italy.

The Amiselimod trial, targeting patients with active, mild to moderate ulcerative colitis (UC), revealed that the drug was well-tolerated and effective in inducing remission. Both doses of Amiselimod led to significant improvements in the Modified Mayo Score compared to a placebo. The trial also showed better endoscopic improvement and clinical remission rates in patients treated with Amiselimod.

At the EASL Conference, Bausch Health presented a comparison of Rifaximin monotherapy with lactulose monotherapy in patients suffering from cirrhosis and a history of overt hepatic encephalopathy (OHE). The analysis demonstrated a lower recurrence rate of OHE episodes in patients treated with Rifaximin, suggesting it as a potent treatment option.

These findings underscore Bausch Health's commitment to advancing therapies for gastrointestinal disorders, aiming to improve patient outcomes globally.